The WHO criteria for staging African trypanosomiasis evaluates the condition using two key inputs: the result of the cerebrospinal fluid trypanosome smear and the cerebrospinal fluid white blood cell count. Based on these inputs, the condition is classified into either the first stage, known as the hemolymphatic stage, or the second stage, known as the meningoencephalitic stage.

Input Parameters:
- Cerebrospinal fluid trypanosome smear:
  - Negative
  - Positive
- Cerebrospinal fluid white blood cell count (cells/mcL):
  - <= 5
  - > 5

The computation involves the following logical checks based on these inputs:

1. If the cerebrospinal fluid trypanosome smear is Negative and the cerebrospinal fluid white blood cell count is <= 5, then the condition is classified as the First (hemolymphatic) stage.
2. If any of the following conditions are met, the condition is classified as the Second (meningoencephalitic) stage:
   - The cerebrospinal fluid trypanosome smear is Positive.
   - The cerebrospinal fluid white blood cell count is > 5.
   - Both the cerebrospinal fluid trypanosome smear is Positive and the cerebrospinal fluid white blood cell count is > 5.
   - Both the cerebrospinal fluid trypanosome smear is Positive and the cerebrospinal fluid white blood cell count is <= 5.
   - The cerebrospinal fluid trypanosome smear is Negative, but the cerebrospinal fluid white blood cell count is > 5.
3. If none of the above conditions can determine the stage, the result states that the stage cannot be fully assessed.

The program will output the determined stage or provide a prompt to complete the inputs if any necessary information is missing. The interpretation relies heavily on whether the trypanosome is detected in the cerebrospinal fluid and whether the white blood cell count exceeds the threshold of 5 cells/mcL. This systematic approach allows for accurate categorization based on these distinct clinical criteria.

The World Health Organization (WHO) criteria for staging of African trypanosomiasis is a clinical tool designed to stratify patients with this disease into distinct stages, which can guide treatment decisions and provide prognostic information. The target patient population for this tool is individuals diagnosed with African trypanosomiasis, a parasitic disease also known as sleeping sickness.

The primary components of the WHO criteria for staging of African trypanosomiasis are the cerebrospinal fluid (CSF) trypanosome smear and the CSF white blood cell (WBC) count. The CSF trypanosome smear is either negative or positive, indicating the presence or absence of the parasite in the CSF. The CSF WBC count is categorized as either less than or equal to 5 cells/mcL or greater than 5 cells/mcL, reflecting the degree of immune response in the CSF.

The stage of African trypanosomiasis is determined based on these two components. The first stage, also known as the hemolymphatic stage, is diagnosed if the CSF trypanosome smear is negative and the CSF WBC count is less than or equal to 5 cells/mcL. The second stage, or meningoencephalitic stage, is diagnosed if the CSF trypanosome smear is positive or the CSF WBC count is greater than 5 cells/mcL. If neither of these conditions is met, the stage of the disease cannot be fully assessed according to the WHO criteria.

This staging system is crucial in the management of African trypanosomiasis, as the stage of the disease determines the appropriate treatment regimen. The first stage of the disease is typically treated with less toxic drugs, while the second stage requires more aggressive treatment due to the involvement of the central nervous system.